Men are more prone to take risks for personal financial gain than women, and women are more likely than men to take risks to protect themselves from financial loss. Pexels

When motorcycle daredevil Evel Knievel leapt over cars, vans and fountains, it was little surprise that the person pulling those stunts was a man. That's not to say women never partake in high-risk behavior (Danica Patrick, anyone?). But decades of research confirm that men really are more inclined to take risks.

Snake River Canyon and the Indy 500 aside, economic life offers plenty of risks as well. When these risks involve investing, men under certain circumstances are more likely than women to take dangerous leaps, but why?

Rice Businesses professor Vikas Mittal joined Xin He of the University of Florida and J. Jeffrey Inman of the University of Pittsburgh in three studies to examine why men and women engage in risky business. Specifically, the team wanted to test whether each gender's risk-taking was moderated by a trait called issue capability: a decision-makers' belief that he or she can solve an issue.

The team grounded their work in agency-communion theory. This posits that men are more driven by goals that further self-interest ("agentic" goals) and women are more driven by goals that further coexistence ("communion" goals).

Based on this theory, the researchers hypothesized that men making investment decisions would take greater risks as their issue capability rose. This would occur because men, who are more focused on maximizing gains, would become more risk-seeking as their self-capability perceptions increased.

Conversely, the researchers theorized, women who faced similar investment decisions would focus on avoiding loss — even when their issue capability rose. This fundamental difference in investing perspective — men trying to maximize any gain versus women trying to minimize any loss – would be at the heart of a diametrically opposite stance on financial risk-taking.

All three studies proved the theory to be correct.

In the first study, the researchers asked men and women to wager money on Daily Double questions in "Jeopardy!" The male contestants with higher issue capability (i.e. demonstrated knowledge of the category) took the biggest risks. The women contestants showed equal levels of betting behavior regardless of whether they had high issue capability or not.

In the second study, the researchers dove into the psychology underlying gender and issue capability. First, the researchers primed male and female participants to believe they had either good or bad track records with risky investment decisions. Then they asked both groups to imagine they could invest $20,000 at varying levels of risk.

When it came to investing for gains, the researchers found, the women's beliefs about their issue capability made no real difference in their financial choices. Even after they had been primed to think they were highly capable investors, the women participants were less prone than the men to focus on the upside potential

And the men? Those who believed they were "capable" made the riskiest investment decisions. They also reported the highest number of thoughts about the positive potential of the various investment scenarios. Statistical analysis proved that these gain-maximization thoughts egged them on in their risk-taking.

On the other hand, those male participants who weren't primed to feel capable showed risk-taking patterns identical to that of the female participants. The results, in other words, suggest that the key difference between men and women's risk-taking is not innate — but stems from their self-conviction in investment competence.

The third study examined these processes in yet another way, by giving female and male participants the chance to maximize gains through making investments in stocks, or to minimize losses through buying insurance. Once again, the men primed to see themselves as ace investors made the riskiest investments. The women who felt themselves especially capable kept their risk-taking steady.

The women's behavior only changed when they thought they were subpar investors. When both women and men were told they were stock market duds, the women were more likely than the men to buy insurance — in other words, to take traditional measures to defend against loss.

Risk-taking choices, in other words, can no longer be written off as just boys being boys or girls being girls. More accurately, boys will be boys when a male investor thinks he is especially capable and that taking a risk will benefit him personally. That's not always a good thing. A female investor, who will typically focus on minimizing potential loss, can contribute a lot to investing decisions. Taking a big risk, as many an investor knows, isn't always the best move.

Mittal's findings inspire a list of possibilities for future research. What will happen to these behaviors as more women assume leadership jobs and more men get to show their skill as caregivers? Should senior management teams have both male and female representation to balance out the upsides and downsides of investment decisions? What about at home: would household decisions change for the better if both the man and the woman contributed their perspective?

------

This story originally ran on Rice Business Wisdom.

Vikas Mittal is the J. Hugh Liedtke Professor of Marketing at Jones Graduate School of Business at Rice University.

Ad Placement 300x100
Ad Placement 300x600

CultureMap Emails are Awesome

Houston startup debuts bio-based 'leather' fashion collection in Milan

sustainable fashion

Earlier this month, Houston-based Rheom Materials and India’s conscious design studio Econock unveiled a collaborative capsule collection that signaled more than just a product launch.

Hosted at Lineapelle—long considered the global epicenter of the world's premier leather supply chain—in the vaulted exhibition halls of Rho-Fiera Milano, the collection centered around Rheom’s 91 percent bio-based leather alternative, Shorai.

It was a bold move, one that shifted sustainability from a concept discussed in panel sessions to garments that buyers could touch and wear.

The collection featured a bomber-style jacket, an asymmetrical skirt and a suite of accessories—all fabricated from Shorai.

The standout piece, a sculptural jacket featuring a funnel neck and dual-zip closure, was designed for movement, challenging assumptions about performance limitations in bio-based materials. The design of the asymmetrical skirt was drawn from Indian armored warrior traditions, according to Rheom, with biodegradable corozo fasteners.

Built as a modular wardrobe rather than isolated pieces, the collection reflects a shared belief between Rheom and Econock in designing objects that adapt to daily life, according to the companies.

The collection was born out of a new partnership between Rheom and Econock, focused on bringing biobased materials to the market. According to Rheom, the partnership solves a problem that has stalled the adoption of many next-gen textiles: supply chain friction.

While Rheom focuses on engineering scalable bio-based materials, New Delhi-based Econock brings the complementary design and manufacturing ecosystem that integrates artisans, circular materials and production expertise to translate the innovative material into finished goods.

"This partnership removes one of the biggest barriers brands face when adopting next-generation materials,” Megan Beck, Rheom’s director of product, shared in a news release. “By reducing friction across the supply chain, Rheom can connect brands directly with manufacturers who already know how to work with Shorai, making the transition to more sustainable materials far more accessible.”

Sanyam Kapur, advisor of growth and impact at Econock, added: “Our partnership with Rheom Materials represents the benchmark of responsible design where next-gen materials meet craft, creativity, and real-world scalability.”

Rheom, formerly known as Bucha Bio, has developed Shorai, a sustainable leather alternative that can be used for apparel, accessories, car interiors and more; and Benree, an alternative to plastic without the carbon footprint. In 2025, Rheom was a finalist for Startup of the Year in the Houston Innovation Awards.

Shorai is already used by fashion lines like Wuxly and LuckyNelly, according to Rheom. The company scaled production of the sugar-based material last year and says it is now produced in rolls that brands can take to market with the right manufacturer.

Houston startup debuts leather alternative fashion collection in Milan

Houston clean energy co. secures $100M to deploy tech on global scale

Going Global

Houston-based Utility Global has raised $100 million in an ongoing Series D round to globally deploy its decarbonization technology at an industrial scale.

The round was led by Ara Partners and APG Asset, according to a news release. Utility plans to use the funding to expand manufacturing, grow its teams and support its commercial developments and partnerships.

“This financing marks a critical step in Utility’s transition from a proven technology to full-scale global commercial execution,” Parker Meeks, CEO and president of Utility Global, said in the release. “Industrial customers are no longer looking for pilots or promises; they need deployable solutions that work within existing assets and deliver true economic industrial decarbonization today that is operationally reliable and highly scalable. Utility’s technology produces both economic clean hydrogen and capture-ready CO2 streams, and this capital enables us to scale and deploy that impact globally with speed, discipline, and rigor.”

Utility Global's H2Gen technology produces low-cost, clean hydrogen from water and industrial off-gases without requiring electricity. It's designed to integrate into existing industrial infrastructure in hard-to-abate assets in the steel, refining, petrochemical, chemical, low-carbon fuels, and upstream oil and gas sectors.

“Utility is tackling one of the most difficult challenges in the energy transition: decarbonizing hard‑to‑abate industrial sectors,” Cory Steffek, partner at Ara Partners and Utility Global board chair, said in the release. “What sets Utility apart is its ability to compete head‑to‑head with conventional fossil‑based solutions on cost and reliability, even as it materially reduces emissions. With this new funding, Utility is well-positioned for its next chapter of commercial growth while maintaining the technical excellence and capital discipline that have defined its development to date.”

Utility Global reached several major milestones in 2025. After closing a $53 million Series C, the company agreed to develop at least one decarbonization facility at an ArcelorMittal steel plant in Brazil. It also signed a strategic partnership with California-based Kyocera International Inc. to scale global manufacturing of its H2Gen electrochemical cells.

The company also partnered with Maas Energy Works, another California company, to develop a commercial project integrating Maas’ dairy biogas systems with H2Gen to produce economical, clean hydrogen.

"These projects were never intended to stand alone. They anchor a deep and growing pipeline of commercial projects now in development globally across steel, refining, chemicals, biogas and other hard-to-abate sectors worldwide, Meeks shared in a 2025 year-in-review note. He added that 2026 would be a year of "focused acceleration to scale."

---

This article originally appeared on EnergyCapitalHTX.com.

Houston Methodist awarded $4M grant to recruit head of Neal Cancer Center

new hire

Armed with a $4 million state grant, the Houston Methodist Academic Institute has recruited a renowned expert in ovarian and endometrial cancer research to lead the Dr. Mary and Ron Neal Cancer Center.

The grant, provided by the Cancer Prevention and Research Institute of Texas, enabled the institute to lure Dr. Daniela Matei away from Northwestern University’s Feinberg School of Medicine in Chicago. There, she is the Diana Princess of Wales Professor in Cancer Research and chief of the Division of Reproductive Science in Medicine.

Matei will succeed Dr. Jenny Chang, who was hired last year to run the Houston Methodist Academic Institute.

At the Neal Cancer Center, located in the Texas Medical Center complex, oncologists work on innovations in cancer research, treatment, and technology. The center opened in 2021 after the Neals donated $25 million to expand Houston Methodist’s cancer research capabilities. It handles about 7,000 new cases each year involving more than two dozen types of cancer.

U.S. News & World Report puts Houston Methodist Hospital at No. 19 among the country’s best hospitals for cancer care, two spots below Chicago’s Northwestern Memorial Hospital. The University of Texas MD Anderson Cancer Center in Houston sits at No. 1 on the list.

Matei’s research related to ovarian and endometrial cancer holds the potential to benefit tens of thousands of American women. The American Cancer Society estimates:

  • 21,010 women in the U.S. will be diagnosed with ovarian cancer, and 12,450 women will die from it.
  • 68,270 women in the U.S. will be diagnosed with endometrial cancer, and 14,450 women will die from it.

Matei is leaving Northwestern in the wake of widespread cuts in federal funding for medical research. The National Institutes of Health (NIH) has canceled or frozen tens of millions of dollars in grants for Northwestern, the Wall Street Journal reports, and the university has been plugging the gaps with its own money.

“The university is totally keeping us on life support,” Matei told the newspaper last year. “The big question is for how long they can do this.”

According to the Wall Street Journal, Matei’s $5 million NIH grant supporting 69 cancer trials has been caught up in the federal funding chaos, so Northwestern stepped in to cover trial expenses such as nurses’ salaries and diagnostic procedures.

Trial participants include some patients with rare, incurable tumors who are undergoing experimental treatments aligned with the genetics of their condition, the newspaper says.

“It’s certainly a life-and-death situation for cancer patients on these trials,” Matei said in 2025.

Matei is among the beneficiaries of more than $15 million in grants approved February 18 by CPRIT’s board. The grants went toward recruiting five cancer researchers to institutions in Texas.

One of those grants, totaling $1.5 million, went to the University of Houston to recruit Akash Gupta, a research scientist at MIT’s Koch Institute for Integrative Cancer Research. The remaining grants went to recruit scientists to The University of Texas at Dallas and The University of Texas Southwestern Medical Center.